We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

By LabMedica International staff writers
Posted on 21 Oct 2021
Print article
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing access to easy and reliable TB testing, especially in high burden countries, low-resource regions.

Built on the proven QuantiFERON-TB Gold Plus technology, QIAreach QuantiFERON-TB is a portable device that enables the ultrasensitive digital detection of TB infection with an end-to-end workflow that is simple and cost efficient, and increases access to reliable Interferon Gamma Release Assay (IGRA) testing. A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria. QIAreach QuantiFERON-TB runs these tests on the digital eHub and eStick system, a true walkaway solution with random access and no calibration or maintenance.

QIAreach QuantiFERON TB testing requires one patient visit and produces an easy-to-read result in 20 minutes after sample incubation, with the ability to record and send results for improved data management, making it ideal for TB screening programs. QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited. QIAGEN will work with commercial distribution partners as well as the Stop TB Partnership’s Global Drug Facility to ensure affordable access across all high burden, low and middle-income countries. In parallel, QIAGEN will continue its close collaboration with a variety of international organizations and public health institutions to help drive scale-up through innovative implementation projects.

“With QIAreach QuantiFERON-TB we have taken a great step towards leaving no one behind when facing a deadly disease like tuberculosis that is preventable and curable. With this groundbreaking new way to detect TB infections we can aid to prevent patients, especially those in high burden countries, from developing the active form of TB,” said Thierry Bernard, CEO of QIAGEN. “It combines QIAGEN’s proven QuantiFERON-TB technology with a very portable and field-friendly digital device to deliver extremely reliable results without the need for complex laboratory infrastructure at effective cost.”

Related Links:
QIAGEN N.V. 

Gold Supplier
Chromogenic Medium
CHROMagar Candida Plus
New
Tips, Pasteur Pipettes and Serological Pipettes
PROMED Tips, Pasteur Pipettes and Serological Pipettes
New
Gold Supplier
Desktop Urine Analyzer
MONOZYME TX2000
New
Malaria Molecular Detection System
HumaLoop M

Print article

Channels

Clinical Chem.

view channel
Image: Illustration is of the Vertical Auto Profile (VAP) Lipid test with clear demarcation of the different lipoprotein classes and subclasses. (Photo courtesy of VAP Diagnostics Laboratory)

Lipoprotein(a) Concentrations Correlate With LDL-C in Diabetic Children

Cardiovascular disease (CVD) is a significant cause of mortality in those with diabetes. Increased apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) have been shown in pediatric patients... Read more

Molecular Diagnostics

view channel
Image: The TruSight RNA Fusion Panel kit provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer samples (Photo courtesy of Illumina)

Targeted RNA-Sequencing Panel Detects Gene Fusions in Solid Tumors

Increasingly, rearrangements resulting in gene fusions have been revealed in multiple tumor types across diverse organ systems. These gene fusions can drive tumorigenesis by altering gene expression and activity.... Read more

Hematology

view channel
Image: Blood smear from a patient with low grade follicular lymphoma in leukemic phase: note cleaved nuclei (coffee bean cells) and scant cytoplasm (Photo courtesy of Kyle Bradley, MD)

Classification of Mature B-Cell Neoplasms Employing Standardized Flow Cytometry

The classification of lymphoid neoplasms integrates clinical, pathological, immunophenotypic, genetic, and molecular data in order to distinguish between mature B-cell lymphoma entities.... Read more

Immunology

view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more

Pathology

view channel
Illustration

Roche Introduces AI-Based Digital Pathology RUO Algorithms for Evaluation of Breast Cancer Markers

Roche (Basel, Switzerland) has announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for... Read more

Industry

view channel
Illustration

Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.